These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24315504)

  • 1. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.
    Aspinall EJ; Weir A; Sacks-Davis R; Spelman T; Grebely J; Higgs P; Hutchinson SJ; Hellard ME
    Int J Drug Policy; 2014 Jan; 25(1):179-82. PubMed ID: 24315504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.
    Spelman T; Morris MD; Zang G; Rice T; Page K; Maher L; Lloyd A; Grebely J; Dore GJ; Kim AY; Shoukry NH; Hellard M; Bruneau J;
    J Epidemiol Community Health; 2015 Aug; 69(8):745-52. PubMed ID: 25814695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing.
    Corson S; Greenhalgh D; Taylor A; Palmateer N; Goldberg D; Hutchinson S
    Drug Alcohol Depend; 2013 Nov; 133(1):172-9. PubMed ID: 23791029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of respondent-driven sampling to enhance understanding of injecting networks: a study of people who inject drugs in Sydney, Australia.
    Paquette DM; Bryant J; De Wit J
    Int J Drug Policy; 2011 Jul; 22(4):267-73. PubMed ID: 21550790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.
    Bruneau J; Zang G; Abrahamowicz M; Jutras-Aswad D; Daniel M; Roy E
    Clin Infect Dis; 2014 Mar; 58(6):755-61. PubMed ID: 24363333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.
    Kim NJ; Jin H; McFarland W; Raymond HF
    Int J Drug Policy; 2015 Dec; 26(12):1238-43. PubMed ID: 26365768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review.
    Caven M; Malaguti A; Robinson E; Fletcher E; Dillon JF
    Int J Drug Policy; 2019 Oct; 72():169-176. PubMed ID: 31109776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injecting practices in sexual partnerships: hepatitis C transmission potentials in a 'risk equivalence' framework.
    Harris M; Rhodes T
    Drug Alcohol Depend; 2013 Oct; 132(3):617-23. PubMed ID: 23664125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a novel scale for measuring interpersonal factors underlying injection drug using behaviours among injecting partnerships.
    Morris MD; Neilands TB; Andrew E; Maher L; Page KA; Hahn JA
    Int J Drug Policy; 2017 Oct; 48():54-62. PubMed ID: 28804051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.
    Palmateer N; Hutchinson S; McAllister G; Munro A; Cameron S; Goldberg D; Taylor A
    J Viral Hepat; 2014 Jan; 21(1):25-32. PubMed ID: 24329854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
    Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
    Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV- and hepatitis C-related risk behaviors among people who inject drugs in Uganda: implications for policy and programming.
    Baluku M; Wamala T; Muhangi D
    Harm Reduct J; 2019 Sep; 16(1):56. PubMed ID: 31481086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research.
    Jones L; Atkinson A; Bates G; McCoy E; Porcellato L; Beynon C; McVeigh J; Bellis MA
    Int J Drug Policy; 2014 Mar; 25(2):204-11. PubMed ID: 24332457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County, Sweden.
    Norden L; Saxon L; Kåberg M; Käll K; Franck J; Lidman C
    Scand J Infect Dis; 2009; 41(10):727-34. PubMed ID: 19688640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.